Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

FDA Releases Biosimilar Guidance, Medicare Will Cover Infliximab-dyyb & More

  |  

References

  1. Ruoff A. FDA completes guidance on developing biosimilars. Bloomberg. 2016 Dec 29.
  2. U.S. Food and Drug Administration. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product: Guidance for industry. 2016 Dec 28.
  3. U.S. Food and Drug Administration. FDA approves Inflectra, a biosimilar to Remicade. 2016 April 5.
  4. Walsh N. Medicare to cover infliximab biosimilar: Cost to system is 15% lower than original Remicade. MedpageToday. 2017 Jan 6.
  5. Janssen Pharmaceutical Co. News release: Janssen submits two applications to FDA seeking approval of Simponi Aria (golimumab) for the treatment of active psoriatic arthritis and active ankylosing spondylitis. 2017 Dec 20.
  6. Deodhar AA, Reveille JD, Harrison DD, et al. Safety and efficacy of intravenous golimumab in adult patients with active ankylosing spondylitis: Results through Week 28 [abstract]. Arthritis Rheumatol. 2016;68(suppl 10).

Related Articles

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    Andrew Brookes / Image Source on Offset

    Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    Rheumatology Drug Updates: Infliximab Biosimilar Gets FDA Approval & More

    April 5, 2016, marks a revolutionary day in the treatment of autoimmune diseases: The U.S. Food and Drug Administration (FDA) approved an infliximab (Remicade) biosimilar, known as Inflectra (infliximab-dyyb). Infliximab-dyyb, which is administered by intravenous infusion, is the first biosimilar drug approved to treat rheumatic disease in the U.S.1 Infliximab-dyyb has received approval for almost…